Cited by 852Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes Management and Education

The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

Open access

ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Hilliard, Marisa E., Isaacs, Diana, Johnson, Eric L., Kahan, Scott, Khunti, Kamlesh, Leon, Jose, Lyons, Sarah K., Perry, Mary Lou, Prahalad, Priya, Pratley, Richard E., Seley, Jane Jeffrie, Stanton, Robert C., Gabbay, Robert A.·2023·Diabetes Care

DOI 10.2337/dc23-s009PMC PMC9810476

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc23-s009

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citation
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation
The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594
Self-citation
Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Self-citation
Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study
Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3754 · Cited by 536
Self-citation
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic Review and Meta-analysis
Yeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Self-citation
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era
Bell, K. J., Smart, C. E., Steil, G. M., Brand-Miller, J. C., King, B., & Wolpert, H. A. (2015) · Diabetes Care · doi:10.2337/dc15-0100 · Cited by 390
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
Eng, C., Kramer, C. K., Zinman, B., & Retnakaran, R. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61335-0 · Cited by 381
International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors
Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., Alexander, C. M., Battelino, T., Ampudia-Blasco, F. J., Bode, B. W., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2316 · Cited by 379
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial
Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30194-8 · Cited by 357
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Riddle, M. C., Bolli, G. B., Ziemen, M., Muehlen-Bartmer, I., Bizet, F., & Home, P. (2014) · Diabetes Care · doi:10.2337/dc14-0991 · Cited by 354
Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis
Tsapas, A., Avgerinos, I., Karagiannis, T., Malandris, K., Manolopoulos, A., Andreadis, P., Liakos, A., Matthews, D. R., & Bekiari, E. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0864 · Cited by 346
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
Henry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 317
Pramlintide as an Adjunct to Insulin Therapy Improves Long-Term Glycemic and Weight Control in Patients With Type 2 Diabetes
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)
Bolli, G. B., Riddle, M. C., Bergenstal, R. M., Ziemen, M., Sestakauskas, K., Goyeau, H., Home, P. D., & on behalf of the EDITION 3 study investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12438 · Cited by 301
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., THOREN, F. A., Xu, J. L., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 299
New insulin delivery recommendations
Frid, A. H., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, L. J., Smith, M. J., Wellhoener, R., Bode, B. W., Hirsch, I. B., et al. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.010 · Cited by 286
New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
Yki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
Giorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Cleary, P. A., Orchard, T. J., GENUTH, S. M., Wong, N. D., Detrano, R., Backlund, J. C., Zinman, B., Jacobson, A. M., Sun, W., Lachin, J. M., et al. (2006) · Diabetes · doi:10.2337/db06-0653 · Cited by 265
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial
Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260
Self-citation
Insulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis
Singh, S. R., Ahmad, F., Lal, A., Yu, C., Bai, Z., & Bennett, H. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081041 · Cited by 241
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Diamant, M., Nauck, M. A., Shaginian, R. M., Malone, J. K., Cleall, S., Reaney, M. D., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 229
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes
Wysham, C., Bhargava, A., CHAYKIN, L. B., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. C. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 227
New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (edition 4)
Home, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial
Lingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220
Efficacy of carbohydrate counting in type 1 diabetes: A systematic review and meta-analysis
Bell, K. J., Barclay, A. W., Petocz, P., Colagiuri, S., & Brand-Miller, J. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70144-x · Cited by 213
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
Monami, M., Marchionni, N., & Mannucci, E. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.007 · Cited by 211
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes ( EDICT ): a randomized trial
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Mortality in type 1 diabetes in the DCCT/EDIC versus the general population
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-2399 · Cited by 194
The cost of diabetes care-an elephant in the room
Riddle, M. C., & Herman, W. H. (2018) · Diabetes Care · doi:10.2337/dci18-0012 · Cited by 191
Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus
Vijan, S., Sussman, J. B., Yudkin, J. S., & Hayward, R. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2894 · Cited by 185
Patient‐directed titration for achieving glycaemic goals using a once‐daily basal insulin analogue: an assessment of two different fasting plasma glucose targets ‐ the TITRATE TM study
Blonde, L., Merilainen, M., Karwe, V., Raskin, P., & TITRATE™ Study Group (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01060.x · Cited by 180
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
Insulin therapy and hypoglycemia
McCall, A. L. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.001 · Cited by 177
Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: Results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (ONSET 1)
Russell-Jones, D., Bode, B. W., De Block, C., Franek, E., Heller, S. R., Mathieu, C., Philis-Tsimikas, A., Rose, L., Woo, V. C., Østerskov, A. B., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1771 · Cited by 177
Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysis
Phung, O. J., Sobieraj, D. M., Engel, S. S., & Rajpathak, S. N. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12233 · Cited by 168
Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
Bartley, P. C., Bogoev, M., Larsen, J., & Philotheou, A. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02407.x · Cited by 159
Adjunctive Therapy with the Amylin Analogue Pramlintide Leads to a Combined Improvement in Glycemic and Weight Control in Insulin-Treated Subjects with Type 2 Diabetes
Ratner, R. E., Want, L. L., Fineman, M. S., Velte, M. J., Ruggles, J. A., Gottlieb, A., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150252924094 · Cited by 156
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP ‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
Pancreas transplantation
Dean, P. G., Kukla, A., Stegall, M. D., & Kudva, Y. C. (2017) · BMJ · doi:10.1136/bmj.j1321 · Cited by 147
Social Determinants of Health, Cost-related Nonadherence, and Cost-reducing Behaviors Among Adults With Diabetes: Findings From the National Health Interview Survey
Patel, M. R., Piette, J. D., Resnicow, K., Kowalski-Dobson, T., & Heisler, M. (2016) · Medical Care · doi:10.1097/mlr.0000000000000565 · Cited by 143
Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis
Buckingham, B. A., Raghinaru, D., Cameron, F., Bequette, B. W., Chase, H. P., Maahs, D. M., Slover, R. H., Wadwa, R. P., Wilson, D. M., Ly, T. T., et al. (2015) · Diabetes Care · doi:10.2337/dc14-3053 · Cited by 140
Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension
Yki-Järvinen, H., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Wardęcki, M., Muehlen-Bartmer, I., Maroccia, M., & Riddle, M. C. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12532 · Cited by 131
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Maiorino, M. I., Chiodini, P., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2017) · Diabetes Care · doi:10.2337/dc16-1957 · Cited by 128
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 121
Cost-related medication non-adherence among U.S. adults with diabetes
Kang, H., Lobo, J. M., Kim, S., & Sohn, M.-W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.016 · Cited by 119
Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: Systematic review and network meta-analysis
Tricco, A. C., Ashoor, H. M., Antony, J., Beyene, J., Veroniki, A. A., Isaranuwatchai, W., Harrington, A., Wilson, C., Tsouros, S., Soobiah, C., et al. (2014) · BMJ · doi:10.1136/bmj.g5459 · Cited by 117
A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses
Maloney, A., Rosenstock, J., & Fonseca, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1307 · Cited by 115
Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial
Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P.-C., Bregman, D. B., & for the Affinity 1 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0075 · Cited by 114
One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension
Riddle, M. C., Yki‐Järvinen, H., Bolli, G. B., Ziemen, M., Muehlen‐Bartmer, I., Cissokho, S., & Home, P. D. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12472 · Cited by 110
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial ( EDITION JP 2)
Terauchi, Y., Koyama, M., Cheng, X., Takahashi, Y., Riddle, M. C., Bolli, G. B., & Hirose, T. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12618 · Cited by 106
Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis
Singh, S., Wright, E. E., Kwan, A. Y. M., Thompson, J. C., Syed, I. A., Korol, E. E., Waser, N. A., Yu, M. B., & Juneja, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12805 · Cited by 101
Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
Mannucci, E., Monami, M., & Marchionni, N. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00934.x · Cited by 96
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
Klaff, L. J., Cao, D., Dellva, M. A., Tobian, J. A., Miura, J., Dahl, D. B., Lucas, J., & Bue‐Valleskey, J. M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14100 · Cited by 93
Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial
Rodbard, H. W., Visco, V. E., Andersen, H., Hiort, L. C., & Shu, D. H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70090-1 · Cited by 91
Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial
Rodbard, H. W., Cariou, B., Zinman, B., Handelsman, Y., Philis‐Tsimikas, A., Skjøth, T. V., Rana, A., Mathieu, C., & The BEGIN Once Long Trial Investigators (2013) · Diabetic Medicine · doi:10.1111/dme.12303 · Cited by 90
Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial
Out, M., Kooy, A., Lehert, P., Schalkwijk, C. A., & Stehouwer, C. D. A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.11.001 · Cited by 84
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83
Association of initiation of basal insulin analogs vs Neutral Protamine Hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes
Lipska, K. J., Parker, M. M., Moffet, H. H., Huang, E. S., & Karter, A. J. (2018) · JAMA · doi:10.1001/jama.2018.7993 · Cited by 76
Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: The STAT study
Akturk, H. K., Snell-Bergeon, J. K., Rewers, A., Klaff, L. J., Bode, B. W., Peters, A. L., Bailey, T. S., & Garg, S. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0200 · Cited by 70
Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D
Blevins, T., Zhang, Q., Frias, J. P., Jinnouchi, H., & Chang, A. M. (2020) · Diabetes Care · doi:10.2337/dc19-2550 · Cited by 69
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
Aroda, V. R., González-Galvez, G., Grøn, R., Halladin, N., Haluzík, M., Jermendy, G., Kok, A., Őrsy, P., Sabbah, M., Sesti, G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30184-6 · Cited by 68
Self-citation
Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes
Taybani, Z. J., Bótyik, B., Katkó, M., Gyimesi, A., & Várkonyi, T. T. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0673-8 · Cited by 61
The Evidence Base for Diabetes Technology: Appropriate and Inappropriate Meta-Analysis
Pickup, J. C. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700617 · Cited by 57
Effect of metformin on glycaemic control in patients with type 1 diabetes: A meta-analysis of randomized controlled trials
Meng, H., Zhang, A., Liang, Y., Hao, J., Zhang, X., & Lu, J. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2983 · Cited by 56
Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis
Vaz, E. C., Porfírio, G. J. M., Nunes, H. R. D. C., & Nogueira, V. D. S. N. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000045 · Cited by 55
Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes
Bergenstal, R. M., Strock, E. S., Peremislov, D., Gibney, M. A., Parvu, V., & Hirsch, L. J. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.12.014 · Cited by 54
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes
Porcellati, F., Lucidi, P., Cioli, P., Candeloro, P., Marinelli Andreoli, A., Marzotti, S., Ambrogi, M., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes Care · doi:10.2337/dc14-0649 · Cited by 52
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
Dose-response effects of insulin glargine in type 2 diabetes
Wang, Z., Hedrington, M. S., Gogitidze Joy, N., Briscoe, V. J., Richardson, M. A., Younk, L., Nicholson, W., Tate, D. B., & Davis, S. N. (2010) · Diabetes Care · doi:10.2337/dc09-2011 · Cited by 44
Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy
Owens, D. R., Traylor, L., Mullins, P. R., & Landgraf, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.022 · Cited by 43
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
Cowart, K. (2020) · Clinical Diabetes · doi:10.2337/cd19-0061 · Cited by 38
Erratum. Insulin Access and Affordability Working Group: Conclusions and Recommendations. Diabetes Care 2018;41;1299–1311
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D. P., Herman, W. H., Nuys, K. V., Powers, A. C., Taylor, S. I., & Yatvin, A. L. (2018) · Diabetes Care · doi:10.2337/dc18-er08 · Cited by 35
Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia
Babu, A., Mehta, A., Guerrero, P., Chen, Z., Meyer, P. M., Koh, C. K., Roberts, R., Schaider, J., & Fogelfeld, L. (2009) · Endocrine Practice · doi:10.4158/ep09117.orr · Cited by 34
Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus
Grant, M., Heise, T., & Baughman, R. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01084-0 · Cited by 30
Effect of Total Daily Dose on Efficacy, Dosing, and Safety of 2 Dose Titration Regimens of Human Regular U-500 Insulin in Severely Insulin-Resistant Patients with Type 2 Diabetes
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Meta‐analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus (在基础—餐时糖尿病治疗方案中使用门冬胰岛素与使用常规人胰岛素对照研究的Meta分析)
Heller, S., Bode, B., Kozlovski, P., & Svendsen, A. L. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12060 · Cited by 28
Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes
Hoogwerf, B. J., Pantalone, K. M., Basina, M., Jones, M. C., Grant, M., & Kendall, D. M. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.11.002 · Cited by 22

Flagged first, then by citations

2 of the 114 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook

Sorted by citations

A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184

See all 852

Authors: ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
ORCID: ElSayed, Nuha A.
Aleppo, Grazia
Aroda, Vanita R.
Bannuru, Raveendhara R.
Brown, Florence M.
Bruemmer, Dennis
Collins, Billy S.
Hilliard, Marisa E.
Isaacs, Diana
Johnson, Eric L.
Kahan, Scott
Khunti, Kamlesh
Lyons, Sarah K.
Perry, Mary Lou
Prahalad, Priya
Pratley, Richard E.
Seley, Jane Jeffrie
Stanton, Robert C.
Gabbay, Robert A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2022-12-12
Volume: 46
Issue: Supplement_1
Pages: S140-S157
ISSN: 0149-5992 (ISSN-L)
DOI: 10.2337/dc23-s009
PMC: PMC9810476
OpenAlex: W4311264067
Semantic Scholar: f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
Cited by: 851
References: 114
Citations by year: 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
FWCI: 28.05
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/journals/pages/license (vor)
Locations: Diabetes Care (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords: glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
MeSH terms: Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks